A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Zhang, Yiqun, Kwok-Shing Ng, Patrick, Kucherlapati, Melanie, Chen, Fengju, Liu, Yuexin, Tsang, Yiu Huen, de Velasco, Guillermo, Jeong, Kang Jin +34 more·2017·Cancer Cell
DOI 10.1016/j.ccell.2017.04.013

Cited by (645)

Items 401–500 of 645

  1. Identification and validation of core genes in tumor-educated platelets for human gastrointestinal tumor diagnosis using network-based transcriptomic analysis
    Yuhong Jiang, Jun He, Xiaobo Wang, Chao Liu, Weihan Zhou, Dekun Liu, Zhushu Guo, Kuijie Liu · 2023 · Platelets
  2. Emerging Roles of Signal Transduction Pathways in Neurodegenerative Diseases. Hunting New Possible Therapeutic Molecular Targets
    Vincenza Rita Lo Vasco · 2023 · OBM Geriatrics
  3. Promoter hypomethylated PDZK1 acts as a tumorigenic gene in glioma by interacting with AKT1
    Xing Ren, Dan Deng, Shasha Xiang, Jianbo Feng · 2024 · Aging
  4. Modulation of the PI3K/mTOR pathways
    Arpine Galstyan, Janice M. Cho, Daniel E. Johnson, Jennifer Rubin Grandis · 2020 · Elsevier eBooks
  5. Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist
    Jayoung Kim, Peng Jin, Wei Yang, Wun‐Jae Kim · 2020 · Korean journal of urology
  6. MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating β‐catenin and predicts poor prognosis
    Yong Yi, Mincheng Yu, Pei‐Yao Fu, Gao Liu, Pei‐Yun Zhou, Ruo‐Yu Guan, Cheng Zhou, Bao‐Ye Sun, Shuang–Jian Qiu · 2021 · Liver International
  7. Role of Tumor Suppressor PTEN and Its Regulation in Malignant Transformation of Endometrium
    Alina M. Perevalova, Vyacheslav S. Kobelev, В Г Сисакян, Lyudmila F Gulyaeva, Vladimir O. Pustylnyak · 2022 · Biochemistry (Moscow)
  8. Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment
    Henry D. McCann, Charlotte E. Johnson, Rachel J. Errington, David Mark Davies, Elaine A. Dunlop, Andrew R. Tee · 2018 · Cancers
  9. An Overview of the Oncogenic Signaling Pathways in Different Types of Cancers
    Afshin Derakhshani, Zeinab Rostami, Sina Taefehshokr, Hossein Safarpour, Reza Vaezi Astamal, Nima Taefehshokr, Nazila Alizadeh, Antonella Argentiero, Nicola Silvestris, Behzad Baradaran · 2020 · Preprints.org
  10. Predicting the Prognosis of Bladder Cancer Patients Through Integrated Multi-omics Exploration of Chemotherapy-Related Hypoxia Genes
    Wensheng Shi, Jiaming Dong, Bowen Zhong, Xiheng Hu, Chunguang Zhao · 2024 · Molecular Biotechnology
  11. Phosphatidic acid as a cofactor of mTORC1 in platinum-based chemoresistance: Mechanisms and therapeutic potential
    Hadi Alizadeh, Sana Kerachian, Keyvan Jabbari, Bahram Mohammad Soltani · 2024 · European Journal of Pharmacology
  12. Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model
    Laura Cecilia Flores-García, José Luis Ventura-Gallegos, Sandra Lorena Romero-Cordoba, Alfredo J. Hernández-Juárez, M. Augusta Naranjo-Meneses, Eduardo García‐García, Juan Pablo Méndez, Alberto Jose Cabrera-Quintero, Antonio Ramírez-Ruíz, Sigifredo Pedraza‐Sánchez et al. · 2022 · PLoS ONE
  13. Tl(I) and Tl(III)-induce genotoxicity, reticulum stress and autophagy in PC12 Adh cells
    Damiana M. Salvatierra Fréchou, Sandra Viviana Verstraeten · 2024 · Archives of Toxicology
  14. Identification of genes that promote PI3K pathway activation and prostate tumour formation
    Jeffrey C. Francis, Amy Capper, Alistair G. Rust, Klea Ferro, Jian Ning, Wei Yuan, Johann Sebastian De Bono, Stephen J. Pettitt, Amanda Swain · 2024 · Oncogene
  15. Targeting Mps1 in combination with paclitaxel inhibits osteosarcoma progression by modulating spindle assembly checkpoint and Akt/mTOR signaling
    Lu Lu, Yuhai Wang, Jian Chen, Li Ye, Qingyang Liang, Feng Li, Chuanchuan Zhen, Kegong Xie · 2021 · Oncology Letters
  16. Copy number alterations and epithelial‑mesenchymal transition genes in diffuse and intestinal gastric cancers in Mexican patients
    Violeta Larios‐Serrato, José Darío Martínez‐Ezquerro, Hilda-Alicia Valdez‐Salazar, Javier Torres, Margarita Camorlinga‐Ponce, Patricia Piña‐Sánchez, Martha Eugenia Ruiz Tachiquín · 2022 · Molecular Medicine Reports
  17. Detection of a novel panel of 24 genes with high frequencies of mutation in gastric cancer based on next-generation sequencing
    Hui-Hui Zeng, Ze Ran Yang, Yebei Qiu, Shoaib Bashir, Yin Li, Meng Qing Xu · 2022 · World Journal of Clinical Cases
  18. Refining sugar's involvement in cholesterol synthesis
    Nicole Fenton, Tina B. Nguyen, Laura Jane Sharpe, Andrew John Brown · 2022 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
  19. Immune Pathways with Aging Characteristics Improve Immunotherapy Benefits and Drug Prediction in Human Cancer
    Xinyue Wang, Shuang Guo, Hanxiao Zhou, Yue Sun, Jing Gan, Yakun Zhang, Wen Zheng, Caiyu Zhang, Xiaoxi Zhao, Jiebin Xiao et al. · 2023 · Cancers
  20. Prognostic value of RGS1 and mTOR Immunohistochemical expression in Egyptian multiple myeloma patients; A single center study
    Nora Hafez, Lobna Refaat, Omnia K. ElGebaly, Hossam M. Elhariry, Mohamed Ghareeb, Lamiaa Abdelfattah Fathalla · 2023 · PLoS ONE
  21. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
    Vandana Gupta Abramson, Mafalda Oliveira, Andrès M.R. Cervantes, Hans P. M. W. Wildiers, Manish R. Patel, Todd Michael Bauer, Philippe Lucien Bedard, Carlos Roberto Becerra, Stephen Lane Richey, Michael C. Wei et al. · 2019 · Breast Cancer Research and Treatment
  22. Genomic landscape analyses in cervical carcinoma and consequences for treatment
    Dominik Diefenbach, Henry Johannes Greten, Thomas Efferth · 2020 · Current Opinion in Pharmacology
  23. Oncogenic Signaling Pathways in Cancer: An Overview
    Afshin Derakhshani, Zeinab Rostami, Sina Taefehshokr, Hossein Safarpour, Reza Vaezi Astamal, Nima Taefehshokr, Nazila Alizadeh, Antonella Argentiero, Nicola Silvestris, Behzad Baradaran · 2020 · Preprints.org
  24. Biological insights from the whole genome analysis of human embryonic stem cells
    Florian T. Merkle, Sulagna Dia Ghosh, Giulio Genovese, Robert E. Handsaker, Seva Kashin, Konrad J. Karczewski, Colm T. O’Dushlaine, Carlos N. Pato, Michele T. Pato, Daniel G. MacArthur et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  25. Design, Synthesis, and Biological Evaluation of Rapamycin Derivatives as the First Mammalian Target of Rapamycin and GLS1 Dual Inhibitors
    Lin Wu, Minglei Lyu, Dong-Quan Gu, Yin Li, Ying Li, Hongsu Zhao, Tongsheng Wang, Feng-Qing Xu, Deling Wu, Wu-Xi Zhou · 2025 · Journal of Medicinal Chemistry
  26. Antibody reliability influences observed mRNA–protein correlations in tumour samples
    Swathi Ramachandra Upadhya, Colm J. Ryan · 2023 · Life Science Alliance
  27. Early Detection of Wellness-to-Disease Transitions in the AI Era: Implications for Pharmacology and Toxicology
    Noa Rappaport, Bartek Nogal, Kevin M. Perrott, Vincenzo Domina, Leroy Hood, Nathan D. Price · 2025 · The Annual Review of Pharmacology and Toxicology
  28. Integrated analysis of the ubiquitination mechanism reveals the specific signatures of tissue and cancer
    Deyu Long, Ruiqi Zhang, Changjian Du, Jiapei Tong, Yu Ni, Yaqi Zhou, Yongchun Zuo, Mingzhi Liao · 2023 · BMC Genomics
  29. Phosphorylation at tyrosine 317 and 508 are crucial for PIK3CA/p110α to promote CRC tumorigenesis
    Ting Wang, Longci Sun, Chengkun Chen, Yingchao Zhang, Baoyu He, Yanhua Zhang, Zhenghe Wang, Hanbing Xue, Yujun Hao · 2023 · Cell & Bioscience
  30. PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells
    Benoît Thibault, Adrien Thole, Romina D’Angelo, Céline Basset, Julie Guillermet‐Guibert · 2025 · Scientific Reports
  31. Global DNA methylation differences involving germline structural variation impact gene expression in pediatric brain tumors
    Fengju Chen, Yiqun Zhang, Wei Li, Fritz Joachim Sedlazeck, Lanlan Shen, Chad J. Creighton · 2025 · Nature Communications
  32. Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
    Carolyn Kay McCourt, Zihan Wei, Kevin M. Kalinsky, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David R. Patton, Paul Mickey Williams, Stanley R. Hamilton et al. · 2025 · Clinical Cancer Research
  33. Feed‐forward activation of STAT3 signaling limits the efficacy of c‐Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment
    Di Zhao, Jie Chen, Yan Wang, Lingyuan Zhang, Jing Zhang, Weimin Zhang, Jiawen Fan, Jinting Li, Qimin Zhan · 2021 · Molecular Carcinogenesis
  34. Diverse Roles and Therapeutic Potentials of Circular RNAs in Urological Cancers
    Song Wang, Yufan Ying, Xueyou Ma, Weiyu Wang, Xiao Wang, Liping Xie · 2021 · Frontiers in Molecular Biosciences
  35. Inaugurating a novel adjuvant therapy in urological cancers: Ferroptosis
    Zhaoxiang Xie, Qianghua Zhou, Cheng Qiu, Dingjun Zhu, Kaiwen Li, Hai Wei Huang · 2022 · Cancer Pathogenesis and Therapy
  36. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/AKT activation and tumorigenesis of pancreatic adenocarcinoma.
    Zhen Cheng Xu, Yan Liu, Zhi Pan, Lei Qin · 2024 · PubMed
  37. JAK3/STAT5 signaling‐triggered upregulation of PIK3CD contributes to gastric carcinoma development
    Qingqing Hu, Ning Dou, Qiong Wu, Yong Gao, Yandong Li, Jingde Chen · 2024 · Journal of Cell Communication and Signaling
  38. Sacral Bioneuromodulation: The Role of Bone Marrow Aspirate in Spinal Cord Injuries
    José Fábio Lana, Annu H. Navani, Madhan Jeyaraman, Napoliane Santos, Luyddy Pires, Gabriel Silva Santos, Izair Jefthé Rodrigues, Douglas Santos, Tomas Mosaner, Gabriel Ohana Marques Azzini et al. · 2024 · Bioengineering
  39. Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth
    Seraina Faes, Tania Santoro, Laëtitia Troquier, Olga De Souza Silva, Olivier Dormond · 2019 · Biochemical and Biophysical Research Communications
  40. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
    Alberto J. Arribas, Eugenio Gaudio, Sara Napoli, Charles Herbaux, Chiara Tarantelli, Roberta Pittau Bordone, Luciano Cascione, Nicolas Munz, Luca Aresu, Jacopo Sgrignani et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  41. The WW domain of IQGAP1 binds directly to the p110α catalytic subunit of PI 3-kinase
    2023
  42. Comparison of somatic variant oncogenicity classification using ClinGen/CGC/VICC guidelines and QIAGEN Clinical Insight Interpret decision support software
    Aarthi Goverdhan, Lisa G. Mullineaux, Amber L. Pryzbylski, Claire Teigen, Kevin C. Halling, Sheryl Krevsky Elkin, Beth A. Pitel · 2025 · Cancer Genetics
  43. Overcoming Curcumin's Limitations: Synthetic Derivatives in Diabetes and Cancer Management
    Adesola Oluwaseun Adeleye, S Moftah Dena, Oluwafemi Omoniyi Oguntibeju, Salam J.J. Titinchi, Chinyerum Sylvia Opuwari · 2025 · Applied Research
  44. Phosphoinositide-dependent kinase 1 (PDK1) in cancer: molecular insights and therapeutic strategies
    Shatha Algheribe, Ayat Zagzoog, Mohamed Boudjelal, Imadul Islam · 2026 · Frontiers in Chemistry
  45. The mechanism of the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma: current developments and future prospects
    Can Zou, Y J Wang, Qiuyan Chen, Jianyou Shi, Xianbo Wu, Quan Luo · 2026 · Frontiers in Oncology
  46. Interactions between the nervous system and PDAC progression: Regulatory mechanisms and therapeutic implications
    Joelson Germano Crispim, Camila Neiva Porto Silva, Moacyr Jesus Barreto de Melo Rêgo, Michelle Melgarejo da Rosa · 2026 · European Journal of Pharmacology
  47. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry
    Aasems Jacob, Jianrong Wu, Jill Kolesar, Eric B. Durbin, Aju Mathew, Susanne M. Arnold, Aman Chauhan · 2021 · Cancer Medicine
  48. Protein biomarkers for subtyping breast cancer and implications for future research: a 2024 update
    Claudius Mueller, Justin B. Davis, Virginia A. Espina · 2024 · Expert Review of Proteomics
  49. Prevalence and clinical implications of PIK3CA aberrations across cancer types: A real-world next-generation sequencing approach
    Junkyu Kim, Hye‐Lim Jang, Jung Young Hong, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Kyoung‐Mee Kim, Deok geun Kim, Jeeyun Lee, Sung Hee Lim · 2025 · Cancer Genetics
  50. High incidence of PI3K pathway gene mutations in South Indian cervical cancers
    Mathew Maria Rose, Shankar Dhamodharan, Sundaramoorthy Revathidevi, Sundaram Reddy Chakkarappan, Mani G Jagadeesan, Subbiah Shanmugam, Hirofumi Nakaoka, Ituro Inoue, Avaniyapuram Kannan Murugan, Arasambattu Kannan Munirajan · 2022 · Cancer Genetics
  51. Moquiniastrum polymorphum subsp. polymorphum extract inhibits the proliferation of an activated hepatic stellate cell line (GRX) by regulating the p27 pathway to generate cell cycle arrest
    Matheus Scherer Bastos, Rafaela Mallmann Saalfeld, Bruna Pasqualotto Costa, Maria Cláudia Rosa Garcia, Krist Helen Antunes, Kétlin Fernanda Rodrigues, Denizar Alberto da Silva Melo, Eliane Romanato Santarém, Jarbas Rodrigues de Oliveira · 2022 · Journal of Ethnopharmacology
  52. Impact of somatic mutations and transcriptomic alterations on cancer aneuploidy
    Keiichi Hatakeyama, Takeshi NAGASHIMA, Keiichi Ohshima, Sumiko Ohnami, Shumpei Ohnami, Yuji Shimoda, Akane Naruoka, Koji Maruyama, Akira Iizuka, Tadashi Ashizawa et al. · 2023 · Biomedical Research
  53. Bromodomain and Extraterminal Domain Protein 2 in Multiple Human Diseases
    Yikang Ji, Wantao Chen, Xu Wang · 2024 · Journal of Pharmacology and Experimental Therapeutics
  54. Quantitative Assessment of Preanalytic Variables on Clinical Evaluation of PI3/AKT/mTOR Signaling Activity in Diffuse Glioma
    Sol Beccari, Esraa Mohamed, Viva Voong, Stephanie Hilz, Marisa Lafontaine, Anny Shai, Yunita Lim, Jerry Martinez, Benjamin Switzman, Ryon L Yu et al. · 2024 · Modern Pathology
  55. Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds
    Claire Blanchard, Alison Gomeiz, Kyle Avery, Emna El Gazzah, Abduljalil M. Alsubaie, Masoumeh Sikaroodi, Ylenia Chiari, Chelsea Ward, Jonathan Sanchez, Virginia A. Espina et al. · 2024 · Cell Communication and Signaling
  56. Translational regulation of SND1 governs endothelial homeostasis during stress
    Zhenbo Han, Gege Yan, Jordan Jousma, S. B. Nukala, Mehdi Amiri, Stephen J. Kiniry, Negar Tabatabaei, Y. Kwon, Sen Zhang, Jalees Rehman et al. · 2025 · Journal of Clinical Investigation
  57. Identifying and validating PLAU as a potential prognostic biomarker for PDAC
    Peng An, Junhong Wang, Rong Fan · 2025 · Scientific Reports
  58. The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice
    Jennifer Jing Huang, James J.-D. Hsieh · 2020 · Kidney Cancer
  59. The Genomic Landscape of Prostate Cancer Brain Metastases
    Antonio Rodrı́guez, John Gallon, Dilara Akhoundova, Sina Maletti, Alison M. Ferguson, Joanna Cyrta, Ursula Amstutz, Andrea Garofoli, Viola Paradiso, Scott A. Tomlins et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  60. Loss of epigenetic regulation disrupts lineage integrity, reactivates multipotency and promotes breast cancer
    Ellen R. Langille, Khalid N. Al‐Zahrani, Zhibo Ma, Ahmad Malik, Sampath Kumar Loganathan, Daniel Trcka, Jeff Liu, Katelyn J. Kozma, Ricky Tsai, Katie Teng et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  61. Verbascoside induces the cell cycle arrest and apoptosis of breast cancer via suppression of the PI3K/AKT signaling pathway
    Yuying Ou, Ye Zhang, Xinbing Zhu, Demiao Zhu · 2022 · Research Square
  62. Nullomer peptide increases immune cell infiltration and reduces tumor metabolism in triple negative breast cancer mouse model
    N. Ali, Cody L. Wolf, Swarna Kanchan, S. Veerabhadraiah, L. Bond, M. Turner, C. Jorcyk, G. Hampikian · 2023 · Research Square
  63. The multifaceted functions of SPC25 in cancer: from molecular pathways to targeted therapy
    Yigang Jin, Minjie Chen, Fei Chen, Zhaofeng Gao, Xiaoping Li, Lingyu Hu, Dandan Cai, Siqi Zhao, Zhengwei Song · 2025 · Frontiers in Medicine
  64. Vaginal Adenocarcinoma: A Review of a Rare Gynecologic Cancer
    Mun-Kun Hong, Dah‐Ching Ding · 2025 · Cancers
  65. Farrerol inhibits proliferation and migration of colorectal cancer via the VEGF signaling pathway: evidence from network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments
    Longhui Zhang, Qinghua Xu, Guanduo Sun, Xiaokang Zhang, Jialong Xue, Chun Yao, Dechun Liu, Jingming Zhai · 2025 · Frontiers in Pharmacology
  66. Genomic landscape of pediatric germ cell tumors reveals oncogenic mutations and copy number alterations
    J. Galvão, Ana Flavia Souza Peres Bezerra, Felipe Antonio de Oliveira Garcia, Ana Glenda Santarosa Vieira, E. C. Albino da Silva, André van Helvoort Lengert, R. M. Reis, L. Lopes, A. Evangelista, M. Pinto · 2026 · Frontiers in Oncology
  67. Crosstalk of Molecular Signaling in Hepatocellular Carcinoma
    Hua-Rong Chen, Jun Yu · 2020 · Springer eBooks
  68. Improving the Genome Annotation of Rhizoctonia solani Using Proteogenomics
    Jiantao Shu, Mingkun Yang, Cheng Zhang, Pingfang Yang, Feng Ge, Ming Li · 2021 · Current Genomics
  69. PIK3CA Mutational Analysis in Patients With Macrodactyly
    Jakob Becker, Ulrike Camenisch Gross, Daniel Max Weber, Lisa Weibel, Martin Theiler, Simone Brandt, Peter K. Bode · 2022 · Pediatric and Developmental Pathology
  70. Altered PI3K/AKT/mTOR Signaling Pathway and Cancer Stem Cells
    Ayse Ertay · 2024 · Stem cell biology and regenerative medicine
  71. Blocking p85β nuclear translocation by importazole enhances Alpelisib efficacy against PIK3CA-helical-domain-mutant tumors
    Baoyu He, Xiangyu Li, Meilian Yao, Yanhua Zhang, Xinyuan Zhou, Jun Gu, Yujun Hao, Dong Zhang, Longci Sun · 2025 · Biochemical and Biophysical Research Communications
  72. Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics
    Francesco Giulio Sullo, Chiara Gallio, Laura Matteucci, Alessandro Bittoni, Margherita Muratore, Luca Esposito, Bianca Ceredi, Graziana Gallo, Paola Ulivi, Ilario Giovanni Rapposelli et al. · 2025 · Expert Opinion on Biological Therapy
  73. Mutational pattern of PIK3CA exon 20 in circulating DNA in breast cancer
    Iman Hassan Ibrahim, Heba Gamal Abd El-Aziz, Noha N. Amer, hesham abd al-samee · 2022 · Saudi Journal of Biological Sciences
  74. Molecular subtype classification of papillary renal cell cancer using miRNA expression
    Changwen Yu, Danjing Dai, Juan Xie · 2019 · OncoTargets and Therapy
  75. Molecular characteristics and clinical implications of serine/arginine-rich splicing factors in human cancer
    Jinjin Zhang, Zhicheng Fang, Congkuan Song · 2023 · Aging
  76. Practical management of renal cell carcinoma: integrating current approaches with advances in bone metastasis treatment
    Irina Anca Eremia, Bogdan Şerban, Mihnea Ioan Gabriel Popa, Adela Iancu, Silvia Nica, Cătălin Cîrstoiu · 2024 · EFORT Open Reviews
  77. Granulocyte‐colony stimulating factor‐producing uterine cervical cancer treated with chemoradiotherapy: A case report with mutation analysis and literature review
    Shintaro Shiba, Takahiro Oike, Ken Ando, Yuya Yoshimoto, Yoshiyasu Takayama, Tatsuya Ohno · 2020 · Clinical Case Reports
  78. Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer
    Iqbal Mohammad Askandar, Siddiqui Shumaila, Asad Ur Rehman, Siddiqui Farid Ahmad, Prithvi Kumar Singh, Bhupender Kumar, Saluja Daman · 2022 · UTUPub (University of Turku)
  79. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types
    Wai Hoong Chang, Alvina Grace Lai · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  80. Transcriptomically-inferred PI3K activity and stemness show a counterintuitive correlation with PIK3CA genotype in breast cancer
    Ralitsa Radostinova Madsen, Oscar M. Rueda, Xavier Robin, Carlos Caldas, Robert K. Semple, Bart Vanhaesebroeck · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  81. Aberrant Signaling Pathways in Cancer
    Luca Grumolato, Stuart A. Aaronson · 2022 · Holland‐Frei Cancer Medicine
  82. Multiple Mutations within Individual Oncogenes: Examples and Clinical Implications
    Keisuke Kataoka, Yuki Saito · 2023 · The Keio Journal of Medicine
  83. Proteomics Analysis of Renal Cell Line Caki-2 with AFMID Overexpression and Potential Biomarker Discovery in Urine
    Jiameng Sun, Jinchun Chang, Zhengguang Guo, Haidan Sun, Jiyu Xu, Xiaoyan Liu, Wei Sun · 2024 · Journal of Proteome Research
  84. RECENT ADVANCES IN SELECTIVELY TARGETING PI3Kα
    David J. St. Jean, Trang Tieu, Angel Guzmán-Pérez, Alexander M. Taylor · 2024 · Medicinal chemistry reviews
  85. Effect of elastin on abnormal proliferation of pulmonary artery smooth muscle cells at an early stage of hypoxic exposure
    Hao Dong, Pengshuai Li, Xuefei Julie Wang, Yuxin Zhang, Fei Han, Shan Gao, Wenqing Hu, Xuewei Hao · 2024 · Journal of Receptors and Signal Transduction
  86. A mode of action protein based approach that characterizes the relationships among most major diseases
    Hongyi Zhou, Brice Edelman, Jeffrey Skolnick · 2025 · Scientific Reports
  87. Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K –Mutated Tumor
    Carolyn Kay McCourt, Jacob Gross, Kevin M. Kalinsky, Ping Guan, Lisa M. McShane, Victoria Wang, Peter James O'Dwyer, Matthew T. Lahey, Cayden Maican, Xiangning Bu et al. · 2025 · JCO Precision Oncology
  88. N-(5-(2-morpholino-4-oxo-3,4-dihydroquinazolin-8-yl)pyridin-2-yl)acylamides as novel multi-PI3K/DNA-PK/P-gp inhibitors for efficient chemosensitization and MDR alleviation
    Martina Sukupova, Karolina Knittelova, Elham Parsimehr, David Maliňák, Denisa Noskova, Jana Kurcova, Ester Marakova, Zdenek Kratochvil, Vladimír Pekařík, Miroslav Psotka et al. · 2025 · European Journal of Medicinal Chemistry
  89. Conventional and alternative approaches for targeting PIK3CA and PTEN alterations in head and neck, breast, and other cancers
    Jovanka Gencel‐Augusto, Jennifer Rubin Grandis, Daniel E. Johnson · 2025 · Advances in Biological Regulation
  90. Early phase development of PI3kinase inhibitors for anticancer therapies
    Carlo Caputo, Angela Lombardi, Miryam DEL VICARIO, Domenico Cautela, Raffaele Addeo, Federica Melisi, Anna Grimaldi, Alois Nečas, Evžen Amler, Rossella Sperlongano et al. · 2025 · Expert Opinion on Investigational Drugs
  91. Targeting PI3Kδ in cancer: a setback or the end
    Zhonglin Hao, Susanne M. Arnold, Jill Kolesar · 2025 · Frontiers in Oncology
  92. Adenovirus E4ORF1 activates isoform-specific phosphatidylinositol 3-kinase signaling in human endothelial cells
    Fuqiang Geng, Mariko Kobayashi, Yang Lin, Jesús M. Gómez-Salinero, Dominick Romano, Jean E. Kanyo, Jennifer Geng, Ying Liu, Michael D. Ginsberg, Jae-Hung Shieh et al. · 2025 · Journal of Biological Chemistry
  93. Multiple Testing of Mix‐and‐Match Feature Sets in Multi‐Omics
    Mitra Ebrahimpoor, Renee Xavier de Menezes, Ningning Xu, Jelle J. Goeman · 2026 · Statistics in Medicine
  94. Chlorella pyrenoidosa-derived extracellular vesicles ameliorate ulcerative colitis through microbiota-mediated AKT/mTOR/ferroptosis pathway
    Danya Lu, X. Chelsea Chen, Demei Wang, Xian Zheng, Tianlong Zhao, Mengmeng Qiu, Ting Li, Lihong Ding, Zhishu Tang, 严宝飞 et al. · 2026 · Phytomedicine
  95. Body fatness and breast cancer risk in relation to phosphorylated mTOR expression in a sample of predominately Black women
    Ting‐Yuan David Cheng, Angela R. Omilian, Song Yao, Weizhou Zhang, Susmita Datta, Wiam Bshara, Rochelle Payne Ondracek, Warren Davis, Song Liu, Chi‐Chen Hong et al. · 2021 · Breast Cancer Research
  96. Identification of Pathway-Based Biomarkers with Crosstalk Analysis for Overall Survival Risk Prediction in Breast Cancer
    Xiaohua Liu, Lili Su, Jingcong Li, Guoping Ou · 2021 · Frontiers in Genetics
  97. [Intrauterine invagination in a newborn infant].
    Wilco C. W. R. Zijlmans, F A Nabben · 1993 · PubMed
  98. Targeting p85β nuclear translocation for the tumors with PIK3CA helical domain mutations
    Baoyu He, Yujun Hao · 2022 · Genes & Diseases
  99. LncRNA CAI2 Contributes to Poor Prognosis of Glioma through the PI3K-Akt Signaling Pathway
    Yu Jiang, Jinhui Zhang, Shengjin Yu, Linlin Zheng, Yue Shen, Weiwei Ju, Lijuan Lin · 2023 · Combinatorial Chemistry & High Throughput Screening
  100. Rare Case of a Turner Syndrome Patient with Metastatic Dysgerminoma and No Y-Chromosomal Material with Pathogenic Variants Found in KIT and MTOR
    Camilla Mains Balle, Christine Gaasdal Kassentoft, Jolinda Iris van Heusden, Michael Knudsen, Line Raaby, Claus Højbjerg Gravholt · 2023 · Sexual Development